Endovascular Development accepted to Uppsala Innovation Centre Business Accelerator

 
Two new companies have now been accepted to UICs accelerator program which supports innovative companies in Uppsala to scale up and increase their growth or grow internationally.  

The program offers companies a unique access to tailored business support and an investment of SEK 500,000. The companies accepted are Endovascular Development and Stardots.

The UIC Business Accelerator business development program accepts innovative companies that are ready to scale up their business further or find a new market. During the program, the companies gain access to specialised knowledge based on the company's unique needs in areas such as law, finance, marketing, leadership or technology. The life science company Endovascular Development and the E-health company Stardots have now been accepted.

Endovascular Development has developed a new Guidewire Fixator which enables safer surgery and reduces operating time along with improving treatments in endovascular surgery.

Stardots, AI-TRUST™ will utilize the cloud and AI to deliver software-as-a-drug for those suffering from Parkinson’s Disease. The digital health platform will significantly improve PD patients’ quality of life, substantially reduce treatment cost and offer an aid to clinical trials for MedTech and pharmaceutical companies.

"These two companies are examples of how UIC attracts innovation that can really make a difference for society as a whole and people as individuals. It will be very interesting to support the companies, partly through the accelerator but also through the investment offered by Linnéa Capital, says Patric Karlsson, Program Manager at UIC.
UIC Business Accelerator runs for two to three years and is for innovative growth companies. The companies are offered tailor-made business development support by hand-picked business coaches from the business community, with specialised skills based on the company's unique needs.

Companies accepted to the accelerator program are also offered an investment of SEK 500,000 from Linnéa Capital. The aim is to strengthen the companies' financial situation and increase growth opportunities. 
 
For more information:
Patric Karlsson, Program Manager and Program Manager UIC Business Accelerator
 UICTel:  +46 705 45 36 75E-mail:  patric.karlsson@uic.se
Vedrana Ilic, kommunikatörUICTel: 0708-51 97 04E-post: 
vedrana.ilic@uic.se
About UIC
UIC (Uppsala Innovation Centre) is one of the country's foremost business incubators and accelerators and is ranked by UBI Global among the world's top 5 best public business incubators. UIC offers tailored business development support, knowledge and networking to innovative startups and growth companies that want to develop their business, scale up or reach an international market. UIC does not take any ownership stakes and is industry independent. UIC works closely with the business community through, for example, a large network of business coaches from the business world and some twenty UIC partners, all of whom contribute to the development of uic companies together with UIC. UIC operates in Uppsala County and Södertälje Municipality. The owners of UIC are equally STUNS, Uppsala Municipality, SLU Holding and Uppsala University Holding. UIC is part of Vinnova's Incubation Support – Excellence program.  www.uic.se

Re-classification of LGF now complete and looking to the future

Endovab is very happy to announce that the medical device re-classification process now is completed: The Liungman Guidewire Fixator CE mark Class 3 (MDD) is valid until May 2024.

We look forward to continuing to supply this key tool to all endovascular centres in Europe, which will help them make interventions in the aorta and the peripheral artery safer and in a shorter time.

2016 > 10

Increased awareness of risks associated with radiation exposure to surgical staff challenge current endovascular methods for treatment of complicated aortic aneurysms.

A retrospective cohort study of 63 EVAR and 63 f/b-EVAR from 2012-2015 at Uppsala University shows that f/b-EVAR procedures are far more complex than conventional EVAR. 
 

The study result shows a remarkably linear relation between number of branched vessel catheterisations and parameters such as use of fluoroscopy, blood-loss, need for intensive care, and anaesthesia and procedure duration. For example, a complete two-vessel f-EVAR lasts on average for 359 minutes (5h 59min), uses 72 minutes of fluoroscopy, and has a total blood loss of 1100ml. Each additional branch catheterisation equals an average of another 98 minutes (1h 38min) procedure duration, 27 minutes of fluoroscopy and 400ml of blood loss.

 

More about this and the LGF approach to reduce the f/b-EVAR challenges will be presented at the Veith Symposium in New York. Wednesday the 15th of November at 10:42, session 41 in the Trianon Ballroom Hilton Hotel.

Läs hela inlägget »

Endovab announced today that it has received CE mark approval for the Liungman Guidewire Fixator, the LGF™.
 
"This is a major landmark for our company and the development of endovascular techniques in general. The LGF is the first ever guidewire that can be anchored distally in an artery while maintaining blood flow. Distal fixation allows parallel work and a range of new endovascular methods and techniques, such as improve the treatment of complicated aortic aneurysms by reducing procedure duration and make more patients eligible for treatment. It also has the added benefit of making procedures more predictable, saving hospitals time and resources” states Linus Bosaeus, CEO of Endovab.
 
Endovab is a medical device development company, founded by vascular surgeon and inventor MD PhD Krister Liungman, former Head of Vascular Surgery at Uppsala University Hospital. The concept of the LGF was initiated after a lifelong career in aortic repair, with the vision to improve endovascular treatment of complicated aortic aneurysms, and a way for the surgeons to maintain guidewire position at all times.
 
The LGF consists of a braided structure of Nickel Titanium, a super elastic memory alloy, which secures the guidewire position through a moderate radial force to the vessel wall. If tension is applied to the guidewire, the braided structure deforms and increases the radial force temporarily to maintain guidewire position, a built-in safety feature prevents over expansion and arterial trauma.
 
The LGF is a really interesting and innovative product that enables new working methods that will improve treatment and push the endovascular frontiers further”, states Professor Anders Wanhainen from Uppsala University, principal investigator for the clinical study.  Scientific board member and thoracic surgery expert professor Tilo Koelbel from the Heart Center in Hamburg comments “Endovab truly has a great team and their disruptive innovation is really impressive in this competitive filed of medical technology”.
 
Over the coming months, the company will introduce the LGF to specialized endovascular clinics for further studies in the field of endovascular aortic repair.
 
Press contact: Linus Bosaeus, linus.bosaeus@endovab.com +46760199975 
Click here to down load the full text: 

Läs hela inlägget »

Thank you ESVS for the opportunity and all you innovative surgeons who engaged us afterwards. More information regarding the guidewire fixator and the facilitated method for f/b-EVAR can be found here.  

Läs hela inlägget »

2016 > 10

Increased awareness of risks associated with radiation exposure to surgical staff challenge current endovascular methods for treatment of complicated aortic aneurysms.

A retrospective cohort study of 63 EVAR and 63 f/b-EVAR from 2012-2015 at Uppsala University shows that f/b-EVAR procedures are far more complex than conventional EVAR. 
 

The study result shows a remarkably linear relation between number of branched vessel catheterisations and parameters such as use of fluoroscopy, blood-loss, need for intensive care, and anaesthesia and procedure duration. For example, a complete two-vessel f-EVAR lasts on average for 359 minutes (5h 59min), uses 72 minutes of fluoroscopy, and has a total blood loss of 1100ml. Each additional branch catheterisation equals an average of another 98 minutes (1h 38min) procedure duration, 27 minutes of fluoroscopy and 400ml of blood loss.

 

More about this and the LGF approach to reduce the f/b-EVAR challenges will be presented at the Veith Symposium in New York. Wednesday the 15th of November at 10:42, session 41 in the Trianon Ballroom Hilton Hotel.

Read the full post »

Endovab announced today that it has received CE mark approval for the Liungman Guidewire Fixator, the LGF™.
 
"This is a major landmark for our company and the development of endovascular techniques in general. The LGF is the first ever guidewire that can be anchored distally in an artery while maintaining blood flow. Distal fixation allows parallel work and a range of new endovascular methods and techniques, such as improve the treatment of complicated aortic aneurysms by reducing procedure duration and make more patients eligible for treatment. It also has the added benefit of making procedures more predictable, saving hospitals time and resources” states Linus Bosaeus, CEO of Endovab.
 
Endovab is a medical device development company, founded by vascular surgeon and inventor MD PhD Krister Liungman, former Head of Vascular Surgery at Uppsala University Hospital. The concept of the LGF was initiated after a lifelong career in aortic repair, with the vision to improve endovascular treatment of complicated aortic aneurysms, and a way for the surgeons to maintain guidewire position at all times.
 
The LGF consists of a braided structure of Nickel Titanium, a super elastic memory alloy, which secures the guidewire position through a moderate radial force to the vessel wall. If tension is applied to the guidewire, the braided structure deforms and increases the radial force temporarily to maintain guidewire position, a built-in safety feature prevents over expansion and arterial trauma.
 
The LGF is a really interesting and innovative product that enables new working methods that will improve treatment and push the endovascular frontiers further”, states Professor Anders Wanhainen from Uppsala University, principal investigator for the clinical study.  Scientific board member and thoracic surgery expert professor Tilo Koelbel from the Heart Center in Hamburg comments “Endovab truly has a great team and their disruptive innovation is really impressive in this competitive filed of medical technology”.
 
Over the coming months, the company will introduce the LGF to specialized endovascular clinics for further studies in the field of endovascular aortic repair.
 
Press contact: Linus Bosaeus, linus.bosaeus@endovab.com +46760199975 
Click here to down load the full text: 

Read the full post »

Thank you ESVS for the opportunity and all you innovative surgeons who engaged us afterwards. More information regarding the guidewire fixator and the facilitated method for f/b-EVAR can be found here.  

Read the full post »

ARCHIVE

LATEST NEWS

Copyright © 2019. Endovascular Development AB. All Rights Reserved.